Lobo Genetics

lobogene.com

Lobo Genetics enables safer cannabis use through DNA testing. Consumers and patients can gain actionable insights into their personal response to cannabis based on their genetic profile. Lobo's portable device platform provides results in under an hour, and can be deployed in medical clinics, dispensaries, pharmacies or retail outlets. With applications across the recreational, medical and clinical space, Lobo is bringing the science of cannabis genetics to everyone.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

news image

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More

Industrial Impact

PRECIGEN ENTERS INTO AGREEMENT TO DIVEST NON-HEALTHCARE SUBSIDIARY TRANS OVA GENETICS

Precigen, Inc. | July 06, 2022

news image

Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out ba...

Read More

Cell and Gene Therapy, Medical

ASHER BIO PRESENTS NEW PRECLINICAL DATA AT ASH APPLYING CIS-TARGETED CYTOKINES TO ENHANCE CAR-T CELL THERAPIES

Asher Bio | December 13, 2022

news image

Asher Biotherapeutics, Inc. a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data demonstrating proof-of-concept for cis-targeted cytokines as a novel strategy for enhancing chimeric antigen receptor T cell engraftment, expansion, and functionality culminating in the delivery of improved anti-tumor activity. This data will be presented in a poster at the 64th American Society of Hematology Annual Me...

Read More

Industrial Impact

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

news image

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More
news image

MARINE BIOTECHNOLOGY MARKET 2020

Publicist 360 | April 08, 2020

IndustryGrowthInsights, 08-04-2020: The research report on the Marine Biotechnology Market is a deep analysis of the market. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Experts have studied the historical data an...

Read More
news image

Industrial Impact

PRECIGEN ENTERS INTO AGREEMENT TO DIVEST NON-HEALTHCARE SUBSIDIARY TRANS OVA GENETICS

Precigen, Inc. | July 06, 2022

Precigen, Inc. a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, announced that the Company has entered into a definitive agreement for the sale of its wholly-owned non-healthcare subsidiary, Trans Ova Genetics, L.C. an industry-leading animal reproductive technologies company, to URUS, a holding company with cooperative and private ownership, for $170 million in upfront cash and up to $10 million earn-out ba...

Read More
news image

Cell and Gene Therapy, Medical

ASHER BIO PRESENTS NEW PRECLINICAL DATA AT ASH APPLYING CIS-TARGETED CYTOKINES TO ENHANCE CAR-T CELL THERAPIES

Asher Bio | December 13, 2022

Asher Biotherapeutics, Inc. a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced new preclinical data demonstrating proof-of-concept for cis-targeted cytokines as a novel strategy for enhancing chimeric antigen receptor T cell engraftment, expansion, and functionality culminating in the delivery of improved anti-tumor activity. This data will be presented in a poster at the 64th American Society of Hematology Annual Me...

Read More
news image

Industrial Impact

FOGPHARMA ANNOUNCES $178 MILLION SERIES D FINANCING TO ADVANCE PIPELINE OF FIRST-IN-CLASS HELICON POLYPEPTIDE THERAPEUTICS TARGETING

FogPharma | November 22, 2022

FogPharma®, a biopharmaceutical company pioneering a new class of precision medicines that could ultimately prove applicable to the vast majority of therapeutic targets, including those previously considered “undruggable,” today announced a $178 Million Series D financing. The financing round includes new investors ARCH Venture Partners, Milky Way Investments and Fidelity Management & Research Company and existing investors VenBio Partners, Deerfield Management, GV, Cormorant...

Read More